Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: First results of the tREACH trial

Annals of the Rheumatic Diseases

Volumn 72, Issue 1, 2013, Pages 72-78

  De Jong, Pascal Hendrik Pieter ^a   Hazes, J M ^a   Barendregt, P J ^b   Huisman, M ^c   Van Zeben, D ^c   Van Der Lubbe, P A ^d   Gerards, A H ^d   De Jager, M H ^e   De Sonnaville, P B ^f   Grillet, B A ^g   Luime, J J ^a   Weel, A E ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital Rotterdam   (Netherlands)

^c Sint Francicus Gasthuis Hospital   (Netherlands)

^d Vlietland Hospital   (Netherlands)

^e ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^f Admiraal de Ruyter Hospital   (Netherlands)

^g ZorgSaam Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; RISEDRONIC ACID; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; VITAMIN D;

ADULT; ARTICLE; BONE MARROW DEPRESSION; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEALTH ASSESSMENT QUESTIONNAIRE; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; KIDNEY FUNCTION; LONELINESS; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCLE WEAKNESS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX QUESTIONNAIRE; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; INDUCTION CHEMOTHERAPY; INJECTIONS, INTRAMUSCULAR; MALE; METHOTREXATE; MIDDLE AGED; RECOVERY OF FUNCTION; SULFASALAZINE;

EID: 84871089146     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201162     Document Type: Article

References (26)

1. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
2. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
3. Smolen JS, Aletaha D, Bijlsma JW, et al . Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 :631-7.
4. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? Arthritis Rheum 2005;52:2975-83. (Pubitemid 41447076)
5. Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and metaanalysis. Ann Rheum Dis 2009;68:1105-12.
6. Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:693-702.
7. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
9. Claessen SJ, Hazes JM, Huisman MA, et al. Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. BMC Musculoskelet Disord 2009;10:71.
10. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
11. van der Heijde DM, van 't Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
12. Siegert CE, Vleming LJ, Vandenbroucke JP, et al. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984;3:305-9. (Pubitemid 15072110)
13. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40. (Pubitemid 26036375)
14. Stucki G, Liang MH, Stucki S, et al. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995;38:795-8.
15. Nederlandse Vereniging van Reumatologie. NVR Richtlijnen medicijnen: Methotrexaat, 2009:1-4.
16. Nederlandse Vereniging van Reumatologie. NVR Richtlijnen medicijnen: Sulfasalazine, 2002:1-6.
17. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9.
18. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90. (Pubitemid 41612204)
19. Alves C, Luime JJ, van Zeben D, et al. Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH). Ann Rheum Dis 2011;70:1645-7.
20. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18. (Pubitemid 27351112)
21. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73. (Pubitemid 29219206)
22. Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010;62:2852-63.
23. Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-4.
24. Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58:73-81.
25. Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
26. Klarenbeek NB, van der Kooij SM, Güler-Yüksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70:315-9.